Key Highlights
- JB Agnus brings over 20 years of biopharmaceutical industry experience to his new role as Chief Business Officer.
- Focus on global business development and building lasting partnerships for KBI’s sustained success.
- JB’s expertise includes biologics, small molecule APIs, ADCs, and cell and gene therapies.
Source: Business Wire
Notable Quotes
- “Our dedication to growth and commitment to our partners, their patients, and our people guide every decision at KBI Biopharma,” – J.D. Mowery, President & CEO at KBI Biopharma
- “Strong partnerships are at the core of KBI’s success. I am excited to join the passionate team at KBI,” – JB Agnus, Chief Business Officer at KBI Biopharma
SoHC's Take
The appointment of Jean-Baptiste Agnus as Chief Business Officer marks a significant milestone in KBI Biopharma’s strategy to expand its global footprint and enhance service offerings in the biopharmaceutical sector. Agnus’s extensive experience and leadership style are expected to drive innovative solutions and partnerships that will not only meet but exceed the evolving needs of KBI’s diverse clientele. His proven track record in fostering collaborative team environments and executing strategic business initiatives offers great promise for KBI’s future endeavors. This strategic hire underscores KBI’s commitment to remaining at the forefront of the CDMO industry by integrating cutting-edge technologies and maintaining high standards of quality and efficiency.
